Skip to main navigation
Skip to search
Skip to main content
Region Zealand Home
Help & FAQ
Link opens in a new tab
Dansk
English
Search content at Region Zealand
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Courses
Press/Media
Impacts
Ingenol mebutate: From common weed to cancer cure
Kian Zarchi
*
, Gregor B.E. Jemec
*
Corresponding author for this work
Dermatology
Research output
:
Contribution to journal
›
Article
›
Research
›
peer-review
Overview
Fingerprint
Fingerprint
Explore the research areas of 'Ingenol mebutate: From common weed to cancer cure'.
Sort by
Weight
Alphabetically
Keyphrases
Actinic Keratosis
100%
Consecutive Days
100%
Microgram
100%
Cancer Cure
100%
Ingenol Mebutate
100%
Common Weeds
100%
Neutrophils
50%
Once-daily
50%
Mechanism of Action
50%
Inflammatory Response
50%
Diclofenac
50%
New Addition
50%
Squamous Cell Carcinoma (SqCC)
50%
5-fluorouracil (5-FU)
50%
Comparative Efficacy
50%
Scalp
50%
Field-directed Therapy
50%
Skin Condition
50%
Side Effect Profile
50%
Trunk
50%
Euphorbia Peplus
50%
Protein Kinase C Inhibitor
50%
Imiquimod
50%
Topical Formulation
50%
Efficacy Rate
50%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Actinic Keratosis
100%
Ingenol Mebutate
100%
Inflammation
50%
Necrosis
50%
Clinical Study
50%
Diclofenac
50%
Squamous Cell Carcinoma
50%
Fluorouracil
50%
Imiquimod
50%
Euphorbia
50%
Protein Kinase C Inhibitor
50%
Side Effect
50%